As of Nov 18, 2026, 1 of 1 active firms rate IMNN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMNN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.56
Range $-0.69 – $-0.44 · 2 analysts · -33% YoY
Next period, 2 analysts expect Imunon Inc to earn $-0.56 a share (range $-0.69 – $-0.44), versus $-0.84 a year earlier. Full-year consensus is $-2.58, growing to $-1.68 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Imunon Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMNN.
#1
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$25.00+3983.6% to target
Overall win rate
24%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$10.00+1533.5% to target
Overall win rate
30%
+ Follow
#3
James Molloy
Alliance Global Partners · Rank #587
Buy
$12.00+1860.1% to target
Overall win rate
25%
+ Follow
IMNN stock forecast FAQ
What is IMNN's average 12-month price target?+
The 1 active firms with a live target average $10.00 for Imunon Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 18, 2026.
Is IMNN stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 18, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover IMNN?+
1 active firms have a recognized rating on Imunon Inc as of Nov 18, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMNN?+
Among analysts who currently cover IMNN, Emily Bodnar of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #521). Their current call is Buy with a $25.00 target.
What is Imunon Inc's projected EPS for next quarter?+
The consensus estimate is $-0.56 per share (range $-0.69 – $-0.44) across 2 analysts. Full-year EPS is projected at $-2.58, rising to $-1.68 the following year.
How much revenue is Imunon Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMNN lately?+
As of Nov 18, 2026, 1 of 1 active firms rate IMNN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMNN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.